Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2025)

Historic Accumulated Depreciation for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $7.8 million.

  • Artiva Biotherapeutics' Accumulated Depreciation rose 4662.91% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 4662.91%. This contributed to the annual value of $5.9 million for FY2024, which is 6769.54% up from last year.
  • Per Artiva Biotherapeutics' latest filing, its Accumulated Depreciation stood at $7.8 million for Q3 2025, which was up 4662.91% from $7.2 million recorded in Q2 2025.
  • Artiva Biotherapeutics' Accumulated Depreciation's 5-year high stood at $7.8 million during Q3 2025, with a 5-year trough of $3.5 million in Q4 2023.
  • Moreover, its 3-year median value for Accumulated Depreciation was $6.2 million (2024), whereas its average is $6.0 million.
  • Per our database at Business Quant, Artiva Biotherapeutics' Accumulated Depreciation surged by 6769.54% in 2024 and then skyrocketed by 4662.91% in 2025.
  • Artiva Biotherapeutics' Accumulated Depreciation (Quarter) stood at $3.5 million in 2023, then skyrocketed by 67.7% to $5.9 million in 2024, then surged by 31.83% to $7.8 million in 2025.
  • Its Accumulated Depreciation was $7.8 million in Q3 2025, compared to $7.2 million in Q2 2025 and $6.5 million in Q1 2025.